Real-world study of lazertinib as second-line or greater treatment in advanced non-small cell lung cancer.

ABSTRACT:

Background

Lazertinib is an oral, third-generation EGFR-TKI, which specifically targets the EGFR T790M mutation along with activating mutations Ex19del and L858R. More real-world data are needed to evaluate its efficacy and safety in treating locally advanced and metastatic non-small cell lung cancer (NSCLC) following prior EGFR TKI treatment.

Methods

This multicenter retrospective study was conducted at seven university hospitals affiliated to the Catholic Medical Center (CMC) in Korea. A clinical data warehouse (CDW) platform was used to access and extract information.

Results

A total of 48 patients were assessed. The majority were female (75%) and diagnosed with adenocarcinoma (95.8%). All patients had the EGFR mutation at diagnosis, 27 (56.3%) had the exon 19 dele

SUBMITTER: Lim JU 

PROVIDER: S-EPMC11219289 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature